By Maria Armental

U.S. health regulators have rejected Perrigo Co.'s (PRGO) generic version of Teva Pharmaceutical Industries Ltd.'s ProAir inhalation aerosol, Perrigo said Friday.

Perrigo, which had targeted releasing the generic in the fourth quarter and had built a roughly 9-cent-a-share projected benefit to its 2018 financial forecast, said it had a teleconference call with the Food and Drug Administration late Thursday afternoon and that it expects to receive what is known as a complete response letter, detailing the reasons for the rejection.

Over all, Perrigo had projected annual profit of $2.90 to $3.30 a share and $5.05 to $5.45 a share on an adjusted basis.

Perrigo's stock fell 4% to $74.10 in after-hours trading while Teva's was down slightly at $19.30.

Write to Maria Armental at maria.armental@wsj.com

(END) Dow Jones Newswires

May 11, 2018 17:13 ET (21:13 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Teva Pharmaceutical Indu...
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Teva Pharmaceutical Indu...